Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 171,815
  • Shares Outstanding, K 48,060
  • Annual Sales, $ 13,260 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 2.36
  • Price/Sales 12.96
  • Price/Cash Flow N/A
  • Price/Book 1.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.50 +2.86%
on 12/15/17
4.75 -24.21%
on 11/27/17
-0.65 (-15.29%)
since 11/15/17
3-Month
3.50 +2.86%
on 12/15/17
11.10 -67.55%
on 10/04/17
-5.75 (-61.50%)
since 09/15/17
52-Week
3.50 +2.86%
on 12/15/17
13.05 -72.41%
on 07/27/17
-3.05 (-45.86%)
since 12/15/16

Most Recent Stories

More News
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

Immune Design (IMDZ) needs investors to pay close attention to the stock based on moves in the options market lately.

IMDZ : 3.60 (+0.70%)
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

-- 39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 patient population receiving G100+pembrolizumab (potential predictive biomarker)

IMDZ : 3.60 (+0.70%)
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.

IMDZ : 3.60 (+0.70%)
Immune Design to Present at Jefferies 2017 London Healthcare Conference

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies...

IMDZ : 3.60 (+0.70%)
Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced seven presentations at the upcoming Connective Tissue Oncology Society (CTOS) and the Society for...

IMDZ : 3.60 (+0.70%)
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

LGND : 135.87 (-0.12%)
IMDZ : 3.60 (+0.70%)
RHHBY : 30.9000 (+0.88%)
SNY : 43.17 (+0.19%)
Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the third quarter ended September 30, 2017.

IMDZ : 3.60 (+0.70%)
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

AGEN : 3.56 (+1.14%)
IMDZ : 3.60 (+0.70%)
CLVS : 64.13 (-0.02%)
RHHBY : 30.9000 (+0.88%)
IMDZ: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/13/2017 settlement date, and Immune Design Corp is one of the most shorted stocks of the Russell 3000, based on 16.37 "days to cover"...

IMDZ : 3.60 (+0.70%)
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.

IMDZ : 3.60 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Key Turning Points

2nd Resistance Point 3.73
1st Resistance Point 3.67
Last Price 3.60
1st Support Level 3.52
2nd Support Level 3.43

See More

52-Week High 13.05
Fibonacci 61.8% 9.40
Fibonacci 50% 8.27
Fibonacci 38.2% 7.15
Last Price 3.60
52-Week Low 3.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.